US equities |
INTC $64.58 ▼-29.85% AMZN $238.65 ▼-2.11% NVDA $203.47 ▼-4.77% MU $875.35 ▼-6.31% SNDK $1,141.89 ▼-14.15% GOOGL $278.93 ▼-1.72% AMD $499.94 ▼-11.74% SPCX $136.93 ▼-4.84%
FinancialContent

Articles published by Cocrystal Pharma, Inc.

News headline image
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Tickers COCP
News headline image
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Tickers COCP
News headline image
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Tickers COCP
News headline image
Cocrystal Pharma to Participate in Two Investor Conferences in November
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Tickers COCP
News headline image
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Tickers COCP
News headline image
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Tickers COCP
News headline image
Cocrystal Pharma to Present at the LD Micro Main Event XV
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Tickers COCP
News headline image
Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Tickers COCP
News headline image
Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Tickers COCP
News headline image
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Tickers COCP
News headline image
Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split
From Cocrystal Pharma, Inc.
Via GlobeNewswire
Tickers COCP